Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 132: DNA and MVA/HIV62B HIV Vaccine Regimen
NCT04041674Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2022
- Primary completion
- Sep 2022
- Modality
- Viral Vector Vaccines, DNA Vaccines
01
Overview
Phase 1, randomised, double-blind trial of pGA2/JS7 DNA vaccine and MVA/HIV62B in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Mar 2022; status: withdrawn.
02
Drugs
pGA2/JS7 DNA vaccineMVA/HIV62B
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04041674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041674.